SQI Diagnostics (FRA:XSQ) Debt-to-Equity : -1.04 (As of Mar. 2023)

View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics Debt-to-Equity?

SQI Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €5.38 Mil. SQI Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €5.01 Mil. SQI Diagnostics's Total Stockholders Equity for the quarter that ended in Mar. 2023 was €-9.95 Mil. SQI Diagnostics's debt to equity for the quarter that ended in Mar. 2023 was -1.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SQI Diagnostics's Debt-to-Equity or its related term are showing as below:

FRA:XSQ's Debt-to-Equity is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

SQI Diagnostics Debt-to-Equity Historical Data

The historical data trend for SQI Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Debt-to-Equity Chart

SQI Diagnostics Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Debt-to-Equity

Get a 7-Day Free Trial

1.57

2.11

2.96

3.16

-1.63

SQI Diagnostics Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															4.64	-9.78	-1.63	-1.37	-1.04

Competitive Comparison of SQI Diagnostics's Debt-to-Equity

For the Diagnostics & Research subindustry, SQI Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQI Diagnostics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's Debt-to-Equity falls into.

SQI Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SQI Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.751	+	6.378)	/	-7.429
	=	-1.63

SQI Diagnostics's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.377	+	5.005)	/	-9.951
	=	-1.04

SQI Diagnostics (FRA:XSQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SQI Diagnostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SQI Diagnostics (FRA:XSQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

36 Meteor Drive, Toronto, ON, CAN, M9W 1A4

Website

https://www.sqidiagnostics.com

SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines